Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy-Reference-Cited by-同舟云学术

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

Published:2021-07-29 Issue:8 Volume:19 Page:2068-2081
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J. Thromb. Haemost.

Author:

Wang Tzu‐Fei¹^ORCID,Baumann Kreuziger Lisa²^ORCID,Leader Avi³⁴^ORCID,Spectre Galia³⁴,Lim Ming Y.⁵^ORCID,Gahagan Andrew⁶,Gangaraju Radhika⁶^ORCID,Sanfilippo Kristen M.⁷,Mallick Ranjeeta⁸,Zwicker Jeffrey I.⁹,Carrier Marc¹

Affiliation:

1. Department of Medicine The Ottawa Hospital and Ottawa Hospital Research Institute University of Ottawa Ottawa Ontario Canada

2. Department of Medicine Medical College of Wisconsin Blood Research Institute Versiti Milwaukee Wisconsin USA

3. Institute of Hematology Davidoff Cancer Center Rabin Medical Center Petah Tikva Israel

4. Sackler School of Medicine Tel Aviv University Tel Aviv Israel

5. Division of Hematology and Hematologic Malignancies Department of Internal Medicine University of Utah Salt Lake City Utah USA

6. Division of Hematology/Oncology Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA

7. Division of Hematology Washington University School of Medicine Saint Louis Missouri USA

8. Clinical Epidemiology Program Ottawa Hospital Research Institute Ottawa Ontario Canada

9. Division of Hemostasis and Thrombosis Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA

Funder

International Society on Thrombosis and Haemostasis

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15367

Reference37 articles.

1. Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis

2. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study

3. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

4. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

5. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies;Thrombosis Research;2023-11

2. Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions;Clinical Pharmacokinetics;2023-10-12

3. Treatment of cancer-associated venous thromboembolism: A focus on special populations;JMV-Journal de Médecine Vasculaire;2023-09

4. Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents;Cancer;2023-07-04

5. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction;The Oncologist;2023-05-12